On November 22, 2022 G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, reported the closing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price of $6.50 per share (Press release, G1 Therapeutics, NOV 22, 2022, View Source [SID1234624335]). G1 Therapeutics received $50,050,000 in gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses. In addition, G1 Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 shares of common stock at the public offering price, less the underwriting discount. Cowen and Raymond James acted as joint book-running managers for the offering. Needham & Company and Wedbush PacGrow acted as lead managers for the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The shares were offered pursuant to a "shelf" registration statement previously filed and declared effective by the Securities and Exchange Commission (the "SEC"). The final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the website of the SEC at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from Cowen and Company, LLC, Attn: Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone: (833) 297-2926 or by email: [email protected]; or from Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, or by telephone at (800) 248-8863, or e-mail at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On November 22, 2022 EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth: EXTX), a Norwegian clinical stage precision health company utilising Acoustic Cluster Therapy (ACT) across multiple therapeutic areas, and the Phoenix-based Translational Genomics Research Institute (TGen), part of City of Hope, reported the publication of a paper in the peer-reviewed Journal of Controlled Release titled "Effect of Acoustic Cluster Therapy combined with chemotherapy in a mouse model of pancreatic cancer" (Press release, Exact Therapeutics, NOV 22, 2022, View Source [SID1234624334]). This study was partly funded by a grant from Innovation Norway.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ACT technology is based on microclusters of microbubble-microdroplets and when sonicated, vaporisation of the microdroplets lead to the formation of larger ACT bubbles. The formation and subsequent oscillation of the ACT bubbles in the microvasculature produces mechanical bio-effects that enhance drug delivery and efficacy. TGen have evaluated the effectiveness of the technology in a preclinical pancreatic cancer model, and the results demonstrated that ACT significantly improved the therapeutic efficacy of two cornerstone treatment regimens in the management of pancreatic cancer. The best effect was seen when drug administration preceded the ACT treatment, but interestingly the anti-tumour effect was almost maintained when the drugs were administered after ACT-treatment was finalized. Similar observations have been made in previous work with ACT combined with chemotherapy. This suggests that the main effect of ACT is not on the drug itself, but rather affects the vasculature and tumour microenvironment to facilitate drug delivery and therapeutic response.

For the full article, please follow: https://www.sciencedirect.com/science/article/pii/S016836592200760X

"Our study demonstrates that ACT can significantly improve the effect of two standard of care chemotherapeutic regimens in a patient-derived pancreatic cancer model in mice. The ACT treatment resulted in a significant increase in tumour growth inhibition and a 7.2 times higher probability of having a complete remission of the tumour compared to the chemotherapeutics alone." said Dr. Haiyong Han, a Professor in TGen’s Molecular Medicine Division and the study’s senior author.

"Pancreatic cancer is known to be notoriously resistant to treatment, in part because of poor drug delivery." said Dr. Daniel Von Hoff, TGen’s Distinguished Professor and one of the national’s lead experts in pancreatic cancer. "The results from the study are some of the most encouraging ones we have seen in preclinical models for pancreatic cancer, and we look forward to being involved in the further development of this promising technology."

Dr Per Walday, CEO of EXACT-Tx, commented: "We are very pleased to announce the publication of these encouraging results from our collaboration with the prestigious Translational Genomics Research Institute in Phoenix, Arizona. These data are produced in a model with patient-derived material, which more closely resembles the tumour tissue characteristics of pancreatic cancer in man compared to cell-line based models. The results further underpin the established potential of ACT to enhance standard of care treatments for difficult to treat cancers and we look forward to progressing our clinical development program in this area."

On November 21, 2022 Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), reported that company management will participate in a fireside chat and 1×1 investor meetings at the 5th Annual Evercore ISI HealthCONx Conference being held virtually November 29 – December 1, 2022 (Press release, Crinetics Pharmaceuticals, NOV 22, 2022, https://crinetics.com/crinetics-pharmaceuticals-to-participate-in-the-5th-annual-evercore-isi-healthconx-conference/ [SID1234624332]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the Crinetics fireside chat are as follows:

Date & Time: November 30, 2022 at 1:00 PM (ET)
Moderator: Josh Schimmer, Research Analyst, Evercore ISI
Webcast Link: View Source
The presentation may be accessed from the Evercore ISI platform or from the Events & Presentations page in the Investors section on the Company’s website. A replay of the presentation will be accessible for 90 days.

In addition, if you are interested in arranging a virtual 1×1 meeting with members of the Crinetics management team, please contact your bank/conference representative.

On November 22, 2022 Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to modulate the tumor microenvironment to elicit a potent and durable anti-tumor response, reported that Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics, will present a corporate overview at the upcoming 34th Annual Piper Sandler Healthcare Conference, in New York, NY on Thursday, December 1, 2022 at 10:10 a.m. ET (Press release, Bicara Therapeutics, NOV 22, 2022, View Source;utm_medium=rss&utm_campaign=bicara-therapeutics-to-present-at-34th-annual-piper-sandler-healthcare-conference [SID1234624330]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 22, 2022 BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, reported that the results of the final progression free survival (PFS) analysis of the ALPINE trial will be presented at a late-breaking oral presentation session at the 64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in New Orleans (Press release, BeiGene, NOV 22, 2022, View Source [SID1234624329]). ALPINE is a global Phase 3 trial comparing BRUKINSA (zanubrutinib) with IMBRUVICA (ibrutinib) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). The results will be presented at 10:15 am CST during the late-breaking abstract session on Tuesday, December 13, 2022 in the Ernest N. Morial Convention Center, Hall E.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In this final PFS analysis, BRUKINSA achieved superior PFS compared with ibrutinib, as assessed by both Independent Review Committee (IRC) and investigator (HR: 0.65 [95% CI, 0.49-0.86] p =.0024, for both investigator and IRC). The PFS results favored zanubrutinib consistently across major pre-defined subgroups including IGHV status and patients with del(17p)/TP53, regardless of IRC or investigator assessment.

"BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy over ibrutinib in any treatment setting; The ALPINE trial results demonstrate superiority for both PFS and ORR versus ibrutinib in relapsed or refractory CLL/SLL," said Mehrdad Mobasher, M.D., M.P.H. Chief Medical Officer, Hematology at BeiGene. "With nearly 30 months of follow up in this trial, we have seen a very consistent safety and tolerability profile for BRUKINSA and look forward to sharing detailed results from this analysis at ASH (Free ASH Whitepaper)."

CLL is one of the most common types of leukemia, accounting for about one-quarter of new cases of leukemiai The condition is characterized by consecutive relapses, with response to therapy ultimately determining clinical benefit, including survival.

At this pre-defined response analysis with a median follow up of 29.6 months, BRUKINSA was generally well-tolerated with a safety profile consistent with previous reports. Overall discontinuation rates were lower with BRUKINSA (26.3%) compared to ibrutinib (41.2%), as well as discontinuations due to adverse events (16.2 vs 22.8%) or progressive disease (7.3 vs 12.9%).

Cardiac safety measures at this analysis favored BRUKINSA compared with ibrutinib: the rate of atrial fibrillation/flutter in the BRUKINSA arm remained low (5.2%) compared with ibrutinib (13.3%) and there were zero grade 5 adverse events due to cardiac disorders with BRUKINSA versus six in the ibrutinib arm.

Investor Events

Sunday, December 11, 2022 – BeiGene will host an ancillary event in New Orleans at 8:00 pm CST for investors and analysts attending ASH (Free ASH Whitepaper). BeiGene senior management will review highlights of the presented data, and special guests will join them for a Q&A panel.
Tuesday, December 13, 2022 – BeiGene will host a webcast following the ALPINE late-breaker presentation at 2:00 pm CST. BeiGene senior management along with invited medical experts will review the presented data and join for a Q&A panel.
Tuesday, December 13, 2022 – BeiGene will host a webcast in Chinese at 6:00 pm CST / December 14, 2022 8:00 am China time to capture Company presentations at ASH (Free ASH Whitepaper). BeiGene senior management will review highlights of the presented data.
These events can be accessed live from the investors section of BeiGene’s website at View Source, View Source or View Source Archived replays will be posted for 90 days following the events.

About BRUKINSA

BRUKINSA is a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies. BRUKINSA was specifically designed to deliver targeted and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared to other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues.

BRUKINSA is supported by a broad clinical program which includes more than 4,700 subjects in 35 trials in more than 30 countries and regions. To date, BRUKINSA is approved in 60 markets, including the United States, China, the European Union Great Britain, Canada, Australia, South Korea, Switzerland, and additional international markets.